

## Supplementary Material

**Article Title:** Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System

**Author(s):** Paul N. Pfeiffer, MD; Jamarie Geller, MD; Dara Ganoczy, MPH; Jennifer Jagusch, MSW; John Carty, MD; Fe Erlita D. Festin, MD; William S. Gilmer, MD; Brian Martis, MD; Mohini Ranganathan, MD; Ilse R. Wiechers, MD; and Avinash Hosanagar, MD

**DOI Number:** <https://doi.org/10.4088/JCP.23m14984>

### **LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE**

1. [Table 1](#) Medication use before and during IV ketamine treatment

### **DISCLAIMER**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

**Supplementary Table 1.** Medication use before and during IV ketamine treatment

Medication or class	Period relative to IV ketamine			
	Year prior		During	
	N	%	N	%
Antidepressant	179	83	136	63
Atypical antipsychotic	97	45	57	27
Lithium	32	15	15	7
Buspirone	18	8	14	7
Liothyronin (T3)	6	3	3	1
Benzodiazepine	70	33	58	27
1st generation antipsychotic	10	5	6	3
Stimulant	38	18	27	13
Anticonvulsant mood stabilizer	63	29	43	20
Gabapentinoid	67	31	46	21
Selective NRI	2	1	2	1
Hypnotic/sleep medication	111	52	94	44
Non-benzodiazepine / Z-drug	30	14	23	11
Melatonin agonist	51	24	41	19
Orexin receptor antagonist	0	0	0	0
Hypnotic antidepressant	68	32	52	24
Hydroxyzine	51	24	27	13

**Class definitions:**

Antidepressants: BUPROPION, CITALOPRAM, DESVENLAFAXINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, LEVOMILNACIPRAN, MIRTAZAPINE, NEFAZODONE, PAROXETINE, SERTRALINE, VENLAFAXINE, VILAZODONE, VORTIOXETINE, AMITRIPTYLINE, AMOXAPINE, CLOMIPRAMINE, DESIPRAMINE, DOXEPIN > 10mg, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, PROTRIPTYLINE, TRIMIPRAMINE, ISOCARBOXAZID, PHENELZINE SULFATE, TRANLYCYPROMINE, SELEGILINE, TRAZODONE > 150mg

Atypical antipsychotics: ARIPIRAZOLE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, PALIPERIDONE, ASENAPINE, ILOPERIDONE, LURASIDONE, BREXPIRAZOLE, CARIPRAZINE, LUMATEPERONE

Benzodiazepines (long-acting): ALPRAZOLAM, CHLORDIAZEPOXIDE, CLONAZEPAM, DIAZEPAM, ESTAZOLAM, LORAZEPAM, OXAZEPAM, PRAZEPAM, TEMAZEPAM

1st generation antipsychotics: CHLORPROMAZINE, CHLORPROTHIXENE, FLUPHENAZINE, HALOPERIDOL, LOXAPINE, MESORIDAZINE, MOLINDONE, PERPHENAZINE, PIMOZIDE, THIORIDAZINE, THIOTHIXENE, TRIFLUOPERAZINE, DROPERIDOL, PROCHLORPERAZINE, TRIFLUPROMAZINE

Stimulants: AMPHETAMINE, DEXTROAMPHETAMINE, METHYLPHENIDATE, AMPHETAMINE/DEXTROAMPHETAMINE, LISDEXAMPHETAMINE, DEXMETHYLPHENIDATE

Anticonvulsant mood stabilizers: DIVALPROEX, VALPROIC ACID, LAMOTRIGINE, CARBAMAZEPINE, OXCARBAZEPINE, TOPIRAMATE

Gabapentinoids: GABAPENTIN, PREGABALIN

Selective norepinephrine reuptake inhibitors (NRIs): ATOMOXETINE, VILOXAZINE

Hypnotic/sleep medications: any non-benzodiazepine, melatonin receptor agonist, orexin receptor antagonist, or hypnotic antidepressant

Non-benzodiazepines / Z-drugs: ZOLPIDEM, ZALEPLON, ESZOPICLONE

Melatonin receptors agonists: MELATONIN, RAMELTEON

Orexin receptor antagonists: SUVOREXANT, DARIDOREXANT, LEMBOREXANT

Hypnotic antidepressants: TRAZODONE ≤ 150mg, DOXEPIN ≤ 10mg